此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

与癌症相关疲劳的小儿脑肿瘤幸存者中的哌醋甲酯 (EMBRAIN)

2026年10月30日 更新者:Odense University Hospital

哌醋甲酯对儿童或青春期治疗脑肿瘤患者癌症相关疲劳的影响:随机,双盲,安慰剂对照的跨界试验的方案 - 拥抱试验

Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking.

The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD).

If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.

研究概览

研究类型

介入性

注册 (估计的)

50

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Aalborg、丹麦、9000
        • 招聘中
        • Aalborg University Hospital
        • 接触:
          • Christina Friis Jensen, Consultant, MD
          • 电话号码:+45 97663368
          • 邮箱:cfj@rn.dk
        • 首席研究员:
          • Christina Friis Jensen, Consultant, MD
      • Aarhus、丹麦、8200
        • 招聘中
        • Aarhus University Hospital
        • 接触:
          • Louise T Henriksen, MD, PhD
          • 电话号码:+45 20921611
          • 邮箱:louhen@rm.dk
        • 首席研究员:
          • Louise T Henriksen, MD, PhD
      • Copenhagen、丹麦、2100
        • 招聘中
        • Rigshospitalet
        • 接触:
        • 首席研究员:
          • Christine Dahl, Consultant, MD, PhD
      • Odense、丹麦、5000
        • 招聘中
        • Odense University Hospital
        • 接触:
        • 首席研究员:
          • Sebastian W Most-Mottelson, MD, PhD Student

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6年 至 27年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Diagnosed and treated for a brain tumor during childhood or adolescence (0-≤18 years).
  2. Treated for a brain tumor during the previous 10 years.
  3. Age ≥6 years and <28 years at the start of the trial.
  4. Off therapy/active treatment for pediatric brain tumor (PBT) for 12 months at the start of the trial.
  5. No known signs of clinical or radiological tumor progression at last follow-up.
  6. Danish is the sole or primary language (enabling provision of validated assessment tools).
  7. Patient and family have provided consent for inclusion in the trial.
  8. Clinically significant fatigue based on the PedsQL MFS questionnaire at baseline, defined by a score ≥ 1 standard deviation below the normative mean.
  9. History of clinically relevant fatigue after treatment of PBT compared to estimated premorbid ability, as assessed from consultations in the childhood cancer outpatient clinics.

Exclusion Criteria:

  1. Any known contraindications to methylphenidate as outlined below:

    A) Hypersensitivity to the active substance or any excipients listed in the summary of product characteristics. B) Glaucoma. C) Pheochromocytoma. D) Hyperthyroidism. E) Mania. F) Psychosis. G) Anorexia nervosa. H) Current or previous severe depression. I) Suicidal behavior. J) Poorly controlled type 1 bipolar affective disorder. K) Antisocial or borderline personality disorder. L) Pre-existing cardiovascular disorders, including severe hypertension, heart failure, arterial occlusive disease, angina pectoris, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening cardiac arrhythmias and channelopathies. M) Pre-existing cerebrovascular disease, cerebral aneurysm, vascular abnormalities including vasculitis or stroke. N) Treatment with irreversible MAO inhibitors within the last 14 days and reversible MAO inhibitors within the last 24 hours.

  2. History of recent poorly controlled seizures.

  3. Complex tics or Tourette syndrome (including family history of tic disorder).

  4. Known diagnosis of Attention Deficit/Hyperactivity Disorder or Autism Spectrum Disorder.

  5. Known diagnosis of Full Scale Intelligence Quotient (FSIQ) of <50.

  6. Pregnancy. Participants known to be pregnant or breastfeeding at screening/registration will not be enrolled in the trial. All sexually active women of childbearing potential (WOCBP) must have a negative pregnancy test prior to the start of treatment. Acceptableeffective contraceptive must be used for the duration of the trial. No further testing is needed during trial, unless the participant suspects to have become pregnant.

  7. Concerns about family ability to safely store or administer MPH, or to report side effects appropriately/concerns about familial substance abuse.

  8. Concurrent use of opiods (ATC N02A) or benzodiazepines (ATC N05BA and N05CF).

  9. Simultaneously enrolled in another clinical trial investigating cancer-related fatigue with a pharmaceutical intervention.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Methylphenidate, Then Placebo

Patients will receive treatment with methylphenidate tablets for 6 weeks, and then cross over to treatment with methylphenidate-matched placebo tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.

10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally.

For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol.

10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally.

Dosage will follow the exact same principles as for the study drug (methylphenidate).

实验性的:Placebo, Then Methylphenidate

Patients will receive treatment with methylphenidate-matched placebo tablets for 6 weeks, and then cross over to treatment with methylphenidate tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.

10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally.

For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol.

10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally.

Dosage will follow the exact same principles as for the study drug (methylphenidate).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
PedsQL Multidimensional Fatigue Scale (MFS)
大体时间:At baseline, at Week 6, Week 16, and Week 20 (follow-up).

Changes in patient self-reported fatigue (participants above 18 years of age) or parent proxy-reported fatigue (participants between 6-17 years of age) from baseline to week 6 of MPH or placebo treatment as measured by the PedsQL Multidimensional Fatigue Scale (MFS).

At baseline, at Week 6, Week 16, and Week 20 (follow-up).

次要结果测量

结果测量
措施说明
大体时间
PedsQL Multidimensional Fatigue Scale (MFS)
大体时间:At baseline, at Week 6, Week 16, and Week 20 (follow-up).

Changes from baseline in self-reported fatigue (participants aged 6-17 years of age) measured by the PedsQL MFS.

At baseline, at Week 6, Week 16, and Week 20 (follow-up).
Behaviour Rating Inventory of Executive Function (BRIEF)
大体时间:At baseline, at Week 6, and Week 16.

Changes from baseline in self and parent-reported executive function measured by the BRIEF-2 or BRIEF-V questionnaire.

At baseline, at Week 6, and Week 16.
Connor's Continuous Performance Test (CPT) Online Suite
大体时间:At baseline, at Week 6, and Week 16.

Changes from baseline in digital measures of sustained attention and executive function. CPT-3 and K-CPT-2 will be used.

At baseline, at Week 6, and Week 16.
Wechsler Coding
大体时间:At baseline, at Week 6, and Week 16.

Changes from baseline in processing speed. Coding module from Wechsler Intelligence Scale for Children Fifth Edition (WISC-V) or Wechsler Adult Intelligence Scale Fifth Edition (WAIS-V) depending on age of participant.

At baseline, at Week 6, and Week 16.
Wechsler Digit Span
大体时间:At baseline, at Week 6, and Week 16.

Changes from baseline in working memory. Coding module from WISC-V or WAIS-V depending on age of participant.

At baseline, at Week 6, and Week 16.
PedsQL Generic Core Scales
大体时间:At baseline, at Week 6, and Week 16.

Changes from baseline in self and parent-reported measures of Health Related Quality of Life.

At baseline, at Week 6, and Week 16.
Accelerometry (Axivity AX3)
大体时间:Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.

Time spent within different activity domains and sleep-wake patterns measured by accelerometry. Axivity AX3 accelerometers will be used.

Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.
Barkley's Stimulant Side Effect Rating Scale (SSERS)
大体时间:At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..

Changes from baseline in self and parent-reported side-effects. A modified version of SSERS with 21 items customized to Danish practice will be used.

At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Mathias Rathe, Consultant, MD, PhD、Odense University Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月2日

初级完成 (估计的)

2029年12月1日

研究完成 (估计的)

2029年12月1日

研究注册日期

首次提交

2024年11月27日

首先提交符合 QC 标准的

2025年3月25日

首次发布 (实际的)

2025年4月1日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年10月30日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • 24/51848
  • R352-A20781 (其他赠款/资助编号:The Danish Cancer Society)
  • 2023-001094 (其他赠款/资助编号:The Danish Childhood Cancer Foundation)
  • 2023-507926-18-00 (克蒂斯)
  • 2023 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅